MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Main trial aims ended up To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though among the exploratory objec... https://simonxrjas.oblogation.com/30373576/the-2-minute-rule-for-qst4